Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy
August 3, 2026 7:20 AM EDTRaymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.
The analyst comments "ALNY shares are -35% since early July on a series of events that have called LT growth potential for... More
